Show simple item record

dc.contributor.authorGonzález Pinto Arrillaga, Ana María ORCID
dc.contributor.authorGonzález Ortega, Itxaso
dc.contributor.authorAlberich, Susana ORCID
dc.contributor.authorRuiz de Azúa García, Sonia ORCID
dc.contributor.authorBernardo, Miguel
dc.contributor.authorBioque, Miquel
dc.contributor.authorCabrera, Bibiana
dc.contributor.authorCorripio, Iluminada
dc.contributor.authorArango, Celso
dc.contributor.authorLobo, Antonio
dc.contributor.authorSánchez Torres, Ana María
dc.contributor.authorCuesta, Manuel J.
dc.contributor.authorPEPs Group
dc.date.accessioned2019-04-17T07:53:30Z
dc.date.available2019-04-17T07:53:30Z
dc.date.issued2016-08-11
dc.identifier.citationPLOS ONE 11(8) : (2016) // Article ID e0160949es_ES
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/10810/32526
dc.description.abstractThe objective of this study is to investigate cognitive performance in a first-episode psychosis sample, when stratifying the interaction by cannabis use and familial or non-familial psychosis. Hierarchical-regression models were used to analyse this association in a sample of 268 first-episode psychosis patients and 237 controls. We found that cannabis use was associated with worse working memory, regardless of family history. However, cannabis use was clearly associated with worse cognitive performance in patients with no family history of psychosis, in cognitive domains including verbal memory, executive function and global cognitive index, whereas cannabis users with a family history of psychosis performed better in these domains. The main finding of the study is that there is an interaction between cannabis use and a family history of psychosis in the areas of verbal memory, executive function and global cognition: that is, cannabis use is associated with a better performance in patients with a family history of psychosis and a worse performance in those with no family history of psychosis. In order to confirm this hypothesis, future research should explore the actual expression of the endocannabinoid system in patients with and without a family history of psychosis.es_ES
dc.description.sponsorshipThe authors would like to thank the following institutions for their funding contributions: the Spanish Ministry of Economy and Competitiveness (Ref. ISCIII 2009-2011:PI 080208), the Instituto de Salud Carlos III-European Fund for Regional Development (PI10/01430, PI10/01746, PI11/01977, PI11/02708, 2011/1064, PI12/02077, PI13/02252, PI13/00451 and PI14/01900, PI11/02831), the Centre for Biomedical Research in the Mental Health Network (CIBERSAM), the Health Department of the Government of Navarre (11/101 and 87/2014), the Government of Catalonia, Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2014SGR441), the Contract FI-DGR-2013 from the Agencia de Gestio d'Ajuts Universitaris i de Recerca, AGAUR (2015 FI_B2 00100 to GM), the Esther Koplowitz Centre (Barcelona), local grants from the Department of Education, Linguistic Policy and Culture of the Basque Country Government, the Basque Foundation for Health Innovation and Research (BIOEF), Madrid Regional Government (S2010/BMD-2422 AGES), European Union Structural Funds and European Union Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7-HEALTH-2009-2.2.1-3-242114 (Project OPTiMISE), FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (Project METSY), Alicia Koplowitz Foundation, Mutua Madrilena Foundation, and the University of the Basque Country (GIC10/80, GIC12/84). The psychiatric research department at Araba University Hospital is supported by the Stanley Research Foundation (03-RC-003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.es_ES
dc.language.isoenges_ES
dc.publisherPublic Library Sciencees_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/ISCIII 2009-2011:PI 080208es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subject1st-episode schizophrenia-patientses_ES
dc.subjectbipolar disorderes_ES
dc.subjectbrain structurees_ES
dc.subjectantipsychotic-drugses_ES
dc.subjectclinical-triales_ES
dc.subjectfollow-upes_ES
dc.subjecthigh-riskes_ES
dc.subjectconsensuses_ES
dc.subjectsiblingses_ES
dc.subjectspectrumes_ES
dc.titleOpposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family Historyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© 2016 González-Pinto et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0160949es_ES
dc.identifier.doi10.1371/journal.pone.0160949
dc.departamentoesNeurocienciases_ES
dc.departamentoeuNeurozientziakes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2016 González-Pinto et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Except where otherwise noted, this item's license is described as © 2016 González-Pinto et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.